Proteus Digital Health Inc. won FDA approval July 30 for technology that helps patients stay on track with their medicines by building sensors into the pills they swallow, but the medical device is bound for pharma as part of an integrated solution to one of health care’s knottiest problems: compliance.
Proteus Digital Health’s Ingestible Sensor Reports When Granny Takes Her Meds
A signal transmitted by the embedded sensor when a pill dissolves is picked up by a Bluetooth-enabled skin patch and sent to a remote phone app, notifying a designated caregiver that dosing is on track – or not. Both Novartis and Otsuka are trying the technology, and Proteus is developing its own line of digitized generics.
More from Archive
• By
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
• By
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
• By
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
• By
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
• By
While the pharma industry appears to be exempt from US tariffs imposed by President Trump, a member of the UK House of Lords says the details are unknown and warned that uncertainty “leads to less investment” in business as a whole.
• By
The EU Clinical Trials Information System has achieved primary registry designation in the International Clinical Trials Registry Platform in a move that is expected to reduce regulatory burden for companies and help them lower compliance costs by aligning with publication requirements in medical journals.
• By
The UK government has listened to industry concerns about high clawback rates under the voluntary scheme and will review it in June in a bid to resolve the issue and “move on to bigger and more important things,” health secretary Wes Streeting says.